HIV vaccine - Abzyme ResearchAlternative Names: Abzentek; E-VAC; Synthetic electrophilic vaccine - Abzyme Research
Latest Information Update: 05 Jan 2016
At a glance
- Originator University of Texas Health Science Center at Houston
- Developer Abzyme Research Foundation; University of Texas Health Science Center at Houston
- Class Viral vaccines
- Mechanism of Action CD4 antigen inhibitors; HIV envelope protein gp120 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical HIV infections